Eli Lilly’s GLP-1 Therapy Breakthrough:Global Peptide API Demand Surges, Highlighting UTIDE’s Guizhou Manufacturing& HK Commercial Capabilities

1. Hot Spot Cut-In: Eli Lilly’s Trial Boosts GLP-1 Peptide API Demand

On January 8, 2026, Eli Lilly and Company announced positive top-line results from its Phase IIIb TOGETHER-PsA study, evaluating the combination of Zepbound (tirzepatide) and Taltz (ixekizumab) for obese or overweight adults with active psoriatic arthritis (PsA). Beyond this specific clinical advancement, the trial underscores a broader industry trend: GLP-1 receptor agonist-based therapies are rapidly expanding their application scope beyond traditional metabolic diseases like diabetes and weight management, driving a sharp increase in global demand for high-quality GLP-1 peptide APIs. This growing market momentum creates significant opportunities for professional peptide API manufacturers with strong production capabilities and global commercial support, such as UTIDE BIOTECH.

Psoriatic arthritis (PsA) is a chronic inflammatory autoimmune disease that often coexists with obesity, bringing significant health burdens to patients. The TOGETHER-PsA trial, as the first controlled study evaluating the combination of a GLP-1 receptor agonist and a PsA biologic, not only provides a new treatment option for this patient group but also signals a key expansion of GLP-1 therapies into autoimmune disease areas—further boosting the global demand for GLP-1 peptide APIs.

2. Market Demand: GLP-1 Boom Triggers Global Peptide API Shortage

The expanding application of GLP-1 therapies has directly fueled the growth of the global peptide API market. According to Frost & Sullivan, the global peptide drug market is expected to reach $210.8 billion by 2030, with GLP-1-based drugs accounting for an increasingly large share thereof—among them, GLP-1 receptor agonist drugs, as the fastest-growing segment, are expected to achieve a compound annual growth rate of over 30%.

This demand boom has further reshaped the global peptide API supply pattern, with China emerging as the world’s primary source of peptide APIs—a shift driven by profound changes in global chemical productivity, as detailed below.

3. Supply Pattern Shift: Core Advantages Make China the Global Peptide API Hub

In recent decades, global chemical production capacity has shifted significantly from Europe and North America to China, largely due to China’s unique advantages tailored to the peptide API sector. First, cost competitiveness: China has lower labor costs and a complete domestic supply chain for core raw materials like amino acids (critical for peptide synthesis), reducing procurement costs and avoiding trade-related supply risks. Pharmaceutical industrial parks in Zunyi, Guizhou and other regions further lower supporting costs for manufacturers.

Second, a comprehensive industrial chain: China boasts a seamless system covering raw material supply, peptide synthesis, purification, quality testing, R&D and pilot testing, enabling rapid responses to global pharmaceutical demand—vital for technically complex peptide APIs.

Third, strong policy support: Biopharmaceuticals and peptide drugs are key in China’s 14th Five-Year Plan for Bioeconomy, with tax breaks, land incentives and subsidies for GMP-compliant manufacturers; local governments also provide "nanny-style" services to accelerate development.

Fourth, advanced environmental compliance and innovation: Chinese manufacturers adopt green synthesis processes to meet global environmental standards while cutting costs, and cooperate with top research institutes to break international monopolies on high-end peptide APIs. These combined advantages have solidified China’s position as the world’s preferred peptide API supplier.

4. Domestic Industry Landscape: Leading Enterprises Drive China’s Peptide API Development

Against this backdrop, China’s peptide API industry has witnessed rapid development, with several leading enterprises emerging as hot players in the global market, driving the overall prosperity of the industry. Companies such as Hanyu Pharmaceutical and Sino Biopharmaceuticals have gained widespread attention for their strong R&D capabilities, large-scale GMP production capacity, and rich GLP-1 peptide API product portfolios. Hanyu Pharmaceutical, for example, has built a differentiated advantage in the GLP-1 sector with its full dosage form layout and large-scale raw material production capacity, while Sino Biopharmaceuticals has achieved significant growth driven by the surging demand for peptide APIs, with its net profit expected to increase substantially. These leading enterprises have not only enhanced China’s influence in the global peptide API market but also laid a solid foundation for the development of other professional peptide API manufacturers, including UTIDE BIOTECH.

5. UTIDE’s Core Competitiveness: Guizhou Manufacturing & HK Commerce Dual-Platform Synergy

As a professional peptide API manufacturer deeply focused on GLP-1-related products, UTIDE BIOTECH has successfully stood out in the increasingly competitive global market, thanks to its unique and integrated "Guizhou production + Hong Kong commerce" dual-platform layout—an advantage that differentiates it from single-production or single-commercial enterprises. This dual-platform model seamlessly integrates the company’s strong manufacturing capabilities rooted in Guizhou and efficient global commercial support based in Hong Kong, enabling UTIDE to not only ensure the stable supply of high-quality GLP-1 peptide APIs through its standardized production base but also provide timely and comprehensive integrated solutions for global biopharmaceutical partners, covering product customization, supply chain coordination, and international compliance services.

5.1 Guizhou Production Base: GMP Compliance & Strong Capacity Ensure Stable Supply

Guizhou Utide Biotechnology Co., Ltd., based in Zunyi, Guizhou—taking advantage of the agglomeration effect of Zunyi’s pharmaceutical industrial park and the region’s favorable supporting policies—serves as UTIDE BIOTECH’s core production base, boasting strong and reliable manufacturing capabilities. The company operates a 20,000-square-meter GMP-compliant manufacturing site with over 200 employees, of which more than 30% are professional and technical personnel engaged in R&D, quality control and production management, specializing in the global supply and integrated solutions of GLP-1-based active pharmaceutical ingredients.

Equipped with advanced automatic peptide synthesis instruments with an annual production capacity of tens of kilograms of high-purity peptide APIs, high-precision purification systems that ensure product purity reaches 99.5% and above, and a full set of high-standard quality testing equipment, including high-performance liquid chromatography (HPLC) and mass spectrometers, the base implements a full-process quality control system from raw material incoming inspection to finished product delivery, with strict batch tracing mechanisms.

This ensures that the purity, activity, and safety of each batch of products fully meet international pharmaceutical standards such as ICH Q7 and comply with the regulatory requirements of major global markets including the EU and the United States. Focusing on peptide APIs in weight management, diabetes, and related therapeutic areas, its core product portfolio includes GLP-1 peptide APIs such as semaglutide and retatrutide—key raw materials for global mainstream GLP-1 drugs, which have passed multiple rounds of quality verification by domestic and foreign customers.

Backed by advanced production equipment, mature peptide synthesis and purification technology accumulated through years of practice, and strict quality control systems, the Guizhou base ensures stable and continuous production of high-quality GLP-1 peptide APIs that meet global pharmaceutical standards, effectively avoiding supply disruptions caused by production instability. In addition, it possesses flexible manufacturing and customization capabilities, capable of providing one-stop customized services from small-batch R&D samples to large-scale commercial production, addressing projects of varying technical complexity to meet the diverse needs of global biopharmaceutical partners in drug R&D, pilot testing and commercial mass production.

5.2 HK Commercial Entity: Professional Team Enables Global Seamless Connection

UTIDE BIOTECH (HK) CO., LIMITED serves as Utide’s dedicated overseas operations and commercial entity, complementing the Guizhou production base with strong global commercial capabilities. As the exclusive platform supporting international business, it is responsible for global contract execution, payment settlement, and logistics coordination, enabling efficient and seamless engagement with customers worldwide. The Hong Kong team, with professional international business experience and rich industry resources, all have over 5 years of experience in the international biopharmaceutical industry, familiar with the regulatory requirements, market characteristics, and business processes of different regions around the world, and have established preliminary cooperation intentions with many well-known pharmaceutical companies in Southeast Asia, Europe, and the Americas. It is committed to building long-term strategic partnerships with global biopharmaceutical companies, providing timely and professional commercial support, and ensuring that high-quality GLP-1 peptide APIs from the Guizhou production base are delivered to global customers efficiently and stably. This "production + commerce" dual-platform synergy enables UTIDE BIOTECH to achieve end-to-end control from production to global supply, providing more reliable and efficient services for global partners.

6. Future Outlook: UTIDE Seizes Opportunities in Peptide API Boom

With the continuous expansion of the global GLP-1 market and the deepening of China’s position as the core peptide API supply base, UTIDE BIOTECH will continue to leverage its advantages: focusing on the Guizhou production base to further enhance manufacturing capacity and product quality, and relying on the Hong Kong commercial platform to expand global market layout and strengthen cooperation with global partners. Committed to becoming a trusted global GLP-1 peptide API supplier, UTIDE BIOTECH will contribute more to the development of the global biopharmaceutical industry and the advancement of human health, seizing the opportunities brought by the booming peptide API market.